Federal Circuit arguments in Myriad may worry biotech industry

The Federal Circuit's Myriad review could provide clarity about the scope of recent Supreme Court patent-eligibility decisions, but one pharma IP practitioner worries that “the biotech industry might feel storm-tossed after these oral arguments”